Which has better earnings & valuation, ABUS or ALEC?

Arbutus Biopharma has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arbutus Biopharma $181.72M 5.67 -$33.50M $0.79 6.59 Alector $21.05M 12.52 -$142.93M -$1.10 N/A

Is ABUS or ALEC more profitable?

Arbutus Biopharma has a net margin of 84.22% compared to Alector's net margin of -850.13%. Arbutus Biopharma's return on equity of 90.98% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 84.22% 90.98% 82.34% Alector -850.13% -531.03% -44.00%

Does the media prefer ABUS or ALEC?

In the previous week, Arbutus Biopharma had 8 more articles in the media than Alector. MarketBeat recorded 9 mentions for Arbutus Biopharma and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Arbutus Biopharma's score of 0.80 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, KURA or ALEC?

Alector has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kura Oncology $77.23M 13.70 -$278.67M -$3.37 N/A Alector $21.05M 12.52 -$142.93M -$1.10 N/A

Is KURA or ALEC more profitable?

Kura Oncology has a net margin of -384.30% compared to Alector's net margin of -850.13%. Kura Oncology's return on equity of -207.18% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Kura Oncology -384.30% -207.18% -45.17% Alector -850.13% -531.03% -44.00%

Does the media refer more to KURA or ALEC?

In the previous week, Kura Oncology had 15 more articles in the media than Alector. MarketBeat recorded 16 mentions for Kura Oncology and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Kura Oncology's score of 0.79 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 7 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, ALEC or PHAR?

Pharming Group has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 12.52 -$142.93M -$1.10 N/A Pharming Group $376.13M 2.23 $2.85M $0.12 98.75

Is ALEC or PHAR more profitable?

Pharming Group has a net margin of 2.51% compared to Alector's net margin of -850.13%. Pharming Group's return on equity of 3.40% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Pharming Group 2.51% 3.40% 1.90%

Does the media favor CADL or ALEC?

In the previous week, Candel Therapeutics had 10 more articles in the media than Alector. MarketBeat recorded 11 mentions for Candel Therapeutics and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Candel Therapeutics' score of 0.14 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alector (ALEC) Competitors

$2.36 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

ALEC vs. ABUS, DSGN, KURA, PHAR, and CADL

Should you buy Alector stock or one of its competitors? Alector's main competitors and comparable companies include Arbutus Biopharma (ABUS), Design Therapeutics (DSGN), Kura Oncology (KURA), Pharming Group (PHAR), and Candel Therapeutics (CADL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alector compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential downside of 4.03%. Alector has a consensus price target of $3.63, indicating a potential upside of 53.60%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Arbutus Biopharma had 8 more articles in the media than Alector. MarketBeat recorded 9 mentions for Arbutus Biopharma and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Arbutus Biopharma's score of 0.80 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$181.72M	5.67	-$33.50M	$0.79	6.59
Alector	$21.05M	12.52	-$142.93M	-$1.10	N/A

Arbutus Biopharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Arbutus Biopharma has a net margin of 84.22% compared to Alector's net margin of -850.13%. Arbutus Biopharma's return on equity of 90.98% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Alector	-850.13%	-531.03%	-44.00%

Summary

Arbutus Biopharma beats Alector on 11 of the 16 factors compared between the two stocks.

How does Alector compare to Design Therapeutics?

Alector (NASDAQ:ALEC) and Design Therapeutics (NASDAQ:DSGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Alector had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Alector and 0 mentions for Design Therapeutics. Alector's average media sentiment score of 1.67 beat Design Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the media.

Company	Overall Sentiment
Alector	Very Positive
Design Therapeutics	Neutral

85.8% of Alector shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 8.3% of Alector shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alector has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Alector currently has a consensus price target of $3.63, suggesting a potential upside of 53.60%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 10.07%. Given Alector's higher probable upside, research analysts clearly believe Alector is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics has a net margin of 0.00% compared to Alector's net margin of -850.13%. Design Therapeutics' return on equity of -34.03% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Design Therapeutics	N/A	-34.03%	-32.05%

Design Therapeutics has lower revenue, but higher earnings than Alector. Design Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	12.52	-$142.93M	-$1.10	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Summary

Design Therapeutics beats Alector on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Kura Oncology currently has a consensus target price of $25.62, suggesting a potential upside of 115.44%. Alector has a consensus target price of $3.63, suggesting a potential upside of 53.60%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Kura Oncology is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Kura Oncology has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Kura Oncology has a net margin of -384.30% compared to Alector's net margin of -850.13%. Kura Oncology's return on equity of -207.18% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Alector	-850.13%	-531.03%	-44.00%

85.8% of Alector shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Kura Oncology had 15 more articles in the media than Alector. MarketBeat recorded 16 mentions for Kura Oncology and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Kura Oncology's score of 0.79 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	7 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alector has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	13.70	-$278.67M	-$3.37	N/A
Alector	$21.05M	12.52	-$142.93M	-$1.10	N/A

Summary

Kura Oncology and Alector tied by winning 8 of the 16 factors compared between the two stocks.

How does Alector compare to Pharming Group?

Alector (NASDAQ:ALEC) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Pharming Group has a net margin of 2.51% compared to Alector's net margin of -850.13%. Pharming Group's return on equity of 3.40% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Pharming Group	2.51%	3.40%	1.90%

85.8% of Alector shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alector presently has a consensus price target of $3.63, suggesting a potential upside of 53.60%. Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 226.30%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Alector had 1 more articles in the media than Pharming Group. MarketBeat recorded 1 mentions for Alector and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.93 beat Alector's score of 1.67 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Alector	Very Positive
Pharming Group	Very Positive

Alector has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Pharming Group has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	12.52	-$142.93M	-$1.10	N/A
Pharming Group	$376.13M	2.23	$2.85M	$0.12	98.75

Summary

Pharming Group beats Alector on 10 of the 15 factors compared between the two stocks.

How does Alector compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Candel Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Candel Therapeutics presently has a consensus target price of $19.29, suggesting a potential upside of 46.88%. Alector has a consensus target price of $3.63, suggesting a potential upside of 53.60%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Candel Therapeutics has a net margin of 0.00% compared to Alector's net margin of -850.13%. Candel Therapeutics' return on equity of -76.98% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Alector	-850.13%	-531.03%	-44.00%

Candel Therapeutics has higher earnings, but lower revenue than Alector. Candel Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Alector	$21.05M	12.52	-$142.93M	-$1.10	N/A

In the previous week, Candel Therapeutics had 10 more articles in the media than Alector. MarketBeat recorded 11 mentions for Candel Therapeutics and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Candel Therapeutics' score of 0.14 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Alector beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$263.52M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-2.15	11.68	272.90	24.25
Price / Sales	12.52	1,350.74	632.64	97.63
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	8.43	17.38	11.25	6.42
Net Income	-$142.93M	-$22.72M	$3.47B	$348.89M
7 Day Performance	15.12%	3.03%	2.33%	0.57%
1 Month Performance	59.46%	9.82%	7.72%	4.90%
1 Year Performance	-6.35%	55.05%	25.22%	17.06%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	2.3514 of 5 stars	$2.36 flat	$3.63 +53.6%	-6.3%	$263.52M	$21.05M	N/A	270	Positive News Gap Down
ABUS Arbutus Biopharma	1.2722 of 5 stars	$4.67 +2.0%	$5.00 +7.1%	+45.1%	$904.72M	$181.72M	5.91	90	Buyback Announcement
DSGN Design Therapeutics	0.7641 of 5 stars	$14.83 +3.1%	$16.50 +11.3%	+185.0%	$900.55M	N/A	N/A	40	Positive News
KURA Kura Oncology	3.1384 of 5 stars	$10.86 +7.6%	$25.62 +135.9%	+55.4%	$895.73M	$77.23M	N/A	130	Insider Trade Gap Up
PHAR Pharming Group	3.9355 of 5 stars	$11.72 -5.1%	$38.67 +229.9%	-13.5%	$874.11M	$376.13M	97.67	280	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. ABUS, DSGN, KURA, PHAR, and CADL

How does Alector compare to Arbutus Biopharma?

Summary

How does Alector compare to Design Therapeutics?

Summary

How does Alector compare to Kura Oncology?

Summary

How does Alector compare to Pharming Group?

Summary

How does Alector compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. ABUS, DSGN, KURA, PHAR, and CADL

How does Alector compare to Arbutus Biopharma?

Do analysts prefer ABUS or ALEC?

Does the media prefer ABUS or ALEC?

Do institutionals and insiders believe in ABUS or ALEC?

Which has better earnings & valuation, ABUS or ALEC?

Which has more volatility and risk, ABUS or ALEC?

Is ABUS or ALEC more profitable?

Summary

How does Alector compare to Design Therapeutics?

Does the media refer more to ALEC or DSGN?

Do insiders and institutionals hold more shares of ALEC or DSGN?

Which has more volatility & risk, ALEC or DSGN?

Do analysts prefer ALEC or DSGN?

Is ALEC or DSGN more profitable?

Which has better earnings & valuation, ALEC or DSGN?

Summary

How does Alector compare to Kura Oncology?

Do analysts recommend KURA or ALEC?

Which has more risk & volatility, KURA or ALEC?

Is KURA or ALEC more profitable?

Do insiders & institutionals hold more shares of KURA or ALEC?

Does the media refer more to KURA or ALEC?

Which has better valuation and earnings, KURA or ALEC?

Summary

How does Alector compare to Pharming Group?

Is ALEC or PHAR more profitable?

Do insiders and institutionals hold more shares of ALEC or PHAR?

Do analysts recommend ALEC or PHAR?

Does the media refer more to ALEC or PHAR?

Which has more risk and volatility, ALEC or PHAR?

Which has higher earnings & valuation, ALEC or PHAR?

Summary

How does Alector compare to Candel Therapeutics?

Which has more volatility and risk, CADL or ALEC?

Do insiders & institutionals have more ownership in CADL or ALEC?

Do analysts recommend CADL or ALEC?

Is CADL or ALEC more profitable?

Which has higher valuation & earnings, CADL or ALEC?

Does the media favor CADL or ALEC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools